title: [Dynamic beta-endorphin determination in hematologic patients].
abstract: OBJECTIVE
  To perform a dynamic study of beta-endorphin, hypoxia-inducible factor-1alpha (HIF-1alpha), and cytokines in hematologic patients.
  
  
  METHODS
  Fifty-nine patients with different types of acute leukemia (AL), 30 with anaplastic anemia (AA), 24 with thrombocytopenic purpura, and 20 healthy volunteers were examined during their 40-day stay at 3200 m above sea level. beta-Endorphin and HIF-la were measured by a sandwich-type enzyme immunoassay using the Abcam antibodies. Cytokines (interleukin (IL)-2, IL-6, and tumor necrosis factor-alpha) were estimated by enzyme immunoassay applying the Pro Con kits (Saint Petersburg).
  
  
  RESULTS
  Serum beta-endorphin concentrations were 1.5-2-fold above the normal values in the majority of patients with AL. The patients with initial leukocytosis at onset of disease were noted to have elevated white blood cell beta-endorphin concentrations up to 85.9 +/- 22.4 pg/ml; moreover, during chemotherapy this index increased about two times (170.74 +/- 33.8 pg/ml). There was a direct correlation between the concentrations of beta-endorphin and HIF-1alpha (r = 0.9) and an inverse correlation between the levels of IL-6 and beta-endorphin (r = -0.7). On ascending to 3200 m, under the conditions of hypoxic hypoxia the patients with AA or idiopathic thrombocytopenic purpura showed a considerable increase in serum beta-endorphin concentrations, mainly in the acute period of being at high altitudes.
  
  
  CONCLUSIONS
  Stress factors (tumor, use of cytostatics, pain, anemia, hypoxia, high environment temperature) stimulate the elaboration of beta-endorphin, particularly in the white blood cells of patients with AL during chemotherapy. The highest elevation in the index was seen during acute adaptation to hypoxic hypoxia.
authors.forename: A B
authors.initials: AB
authors.lastname: Makeshova
authors.forename: Iu I
authors.initials: IuI
authors.lastname: Mamukova
authors.forename: A A
authors.initials: AA
authors.lastname: Levina
authors.forename: E P
authors.initials: EP
authors.lastname: Sysoeva
authors.forename: M O
authors.initials: MO
authors.lastname: Éralieva
authors.forename: V G
authors.initials: VG
authors.lastname: Savchenko
mesh_terms: D000208:Acute Disease; D000531:Altitude; D000741:Anemia, Aplastic / Q000473:pathology*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D007124:Immunoenzyme Techniques; D007376:Interleukin-2 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D007938:Leukemia / Q000188:drug therapy / Q000473:pathology*; D011696:Purpura, Thrombocytopenic / Q000473:pathology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D001615:beta-Endorphin / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007376:Interleukin-2; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D001615:beta-Endorphin